Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Core Viewpoint - Kuros Biosciences has reported a significant financial performance for the first nine months of 2025, with a 77% year-over-year revenue increase, prompting the company to raise its sales guidance for 2025 to at least 70% growth [1][3][10]. Financial & Operational Highlights - Total group revenue reached USD 101.1 million, up 77% compared to USD 57.2 million in the same period of 2024 [3][7]. - Revenue from Direct MagnetOs product sales increased by 76% year-on-year to USD 99.7 million, compared to USD 56.7 million in 9M 2024 [3][7]. - The Group achieved an EBITDA of USD 7.4 million for the first nine months of 2025, a significant increase from USD 1.6 million in the prior-year period [4][7]. - Adjusted EBITDA amounted to USD 12.2 million, with a margin of 12.1%, up from USD 6.5 million and a margin of 11.3% in 9M 2024 [4][7]. - Cash and cash equivalents increased to USD 20.0 million as of September 30, 2025, from USD 18.4 million as of June 30, 2025 [5][7]. Regulatory, Commercial & Clinical Highlights - Kuros has commenced the full commercial launch of the MagnetOs MIS Delivery System in the U.S. after receiving FDA clearance, designed for minimally invasive spine procedures [6][10]. - The MagnetOs MIS Delivery System is noted for its efficiency, delivering grafts three times faster than traditional methods, and is backed by Level I clinical evidence [6][10]. - The company received approval from the Saudi Food and Drug Authority (SFDA) for MagnetOs Putty and MagnetOs Granules, marking a key milestone in its expansion in the MENA region [8][9]. Outlook - The Group expects sales in the second half of the year to align with usual seasonal trends, reinforcing the raised sales guidance for 2025 [3][10]. - The CEO emphasized the company's focus on organic growth initiatives and expansion into new markets, including the spinal market and regions like Saudi Arabia [10].